

Agenda

Tuesday, March 24

07:00-08:30 **Registration**

8:30-08:40 **Welcome Remarks**

08:40-09:00 **Opening Remarks**

09:00-10:00 **Plenary**
From Trials to Triumph: Implementation and Real-World Impact of Vaccination

This plenary opens the conference by highlighting what we are learning from the real-world implementation of TCVs. The session brings together perspectives on global data, country implementation, and specific outcomes that reflect real-world impact.

10:00-10:30 **Coffee Break**
Poster Viewing

10:30-12:30 **Abstract Session**
The Power of Protection: Real-World Vaccine Performance

- Effectiveness of the TYPHIBEV® (Vi-CRM197 conjugate) vaccine introduction in Nepal: a test-negative, case-control study
Dipesh Tamrakar, Dhulikel Hospital, Kathmandu University Hospital, Nepal
- Assessing the Long-term Protection of Typhoid Conjugate Vaccine among Bangladeshi Children: Evidence from a Cluster Randomised Trial
Farhana Khanam, icddr,b, Bangladesh
- Immunogenicity of a Heterologous Typhoid Conjugate Vaccine Booster with different dosing intervals, in Nepali children: An Observational Study
Huma Subhani, Patan Academy of Health Sciences, Nepal
- Medium-term Effectiveness of Typhoid Conjugate Vaccine in Nepal: Evidence from TyVAC and TyVOID study
Shrijana Shrestha, Patan Academy of Health Sciences, Nepal
- Antibody Response and Safety After Booster Vaccination with Heterologous Typhoid Conjugate Vaccine 5–6 Years After Primary Vaccination in Burkinabe Children
Jean W. Sawadogo, Groupe de Recherche Action en Santé, Burkina Faso
- From Crisis to Control: A Study of Typhoid Conjugate Vaccine Impact in Harare, Zimbabwe (2017–2024)
Talent Bvochora-Mudavanhu, Harare City Health Department, Zimbabwe
- Two Year Outcome of an Island-Wide Typhoid Vaccination Campaign in the Northern Division of Fiji

- Alumita Vuakanisakea, International Vaccine Institute (Ty-Five Project), Fiji*
- Evaluating the Impact of Typhoid Conjugate Vaccine Introduction on Typhoid Burden in Pakistan
Farah Naz Qamar, Aga Khan University

12:30-14:00	Lunch
13:00-14:00	<p>Workshop</p> <p>Tackling Invasive Non-Typhoidal Salmonella in Africa: Integrating Genomics, Epidemiology, and One Health Strategies for Sustainable Antimicrobial Resistance and Disease Control</p> <p>Moderators: Melita Gordon and John Crump</p> <ul style="list-style-type: none"> Carriage and shedding of MDR iNTS strains in children in Kenyan children: Genomic characterization and vaccine implication <i>Kelvin Kering, KEMRI</i> Longitudinal high-resolution household transmission dynamics and latent infection modelling of NTS in Malawi <i>Peter Johnston, University of Liverpool, Malawi Liverpool Wellcome Programme</i> Genomic and metagenomic insights into environmental reservoirs of nontyphoidal salmonella among children in a disease-endemic, resource-challenged setting <i>Collins Kebenei, KEMRI</i> Leveraging sero-epidemiological and functional immunological findings from 4 contrasting African site cohorts, to understand iNTS exposure and protection <i>Helen Dale, University of Edinburgh</i> <p>Panel Discussion</p> <ul style="list-style-type: none"> <i>Megan Carey, MMGH Consulting GmbH</i> <i>Stefano Malvolti, MMGH Consulting GmbH</i> <i>Gianluca Bregghi, Sclavo Vaccines Association</i>
14:00-15:30	<p>Symposium</p> <p>Turning the Tide on Typhoid: TCV Introduction and Impact</p> <p>Moderators: Emmanuel Mugisha and Farah Qamar</p> <ul style="list-style-type: none"> Mobilizing momentum: How Burkina Faso reached 10 million children in seven days <i>Eric Nebie, PATH, Burkina Faso</i> Equity and complexity: school-based vaccination during the MR/TCV campaign in Kenya <i>Rose Jalang'o, National Vaccine & Immunization Program, Kenya</i> Equity at scale: Bangladesh's road to reaching more than 40 million children with TCV <i>Muhibul Kashem, PATH, Bangladesh</i> Vaccines of equity: Reaching an extended age cohort with TCV and MMCV in Niger <i>Rachidou Souley, Ministry of Public Health, Population, and Social Affairs, Niger</i> Impact of TCV on antimicrobial use among suspected typhoid fever patients in Pakistan <i>Megan Carey, LSHTM, UK</i> Modelling the Initial Impact and Predicted Future Benefits of TCV in Pakistan <i>Alicia N. M. Kraay, Institute for Disease Modelling/Bill & Melinda Gates Foundation, USA</i>
15:30-16:00	<p>Coffee Break</p> <p>Poster Viewing</p>

16:00-17:30

Abstract Session

Keeping a Watchful Eye: Surveillance and Burden of Disease

- Environmental Surveillance to Complement Clinical Surveillance in the Context of TCV Introduction in the Northern Division of Fiji
Raphael Zellweger, International Vaccine Institute (IVI), South Korea
- Using Population-based and School-Based Rapid Serosurveys to Characterize Geographic and Age Variability of Enteric Fever burden in Pakistan
Mehreen Adnan, University of Oxford, UK
- Seroepidemiology and serum bactericidal activity of IgG antibodies to Non typhoidal Salmonella in healthy Children in Mukuru informal settlement in Kenya
Schola Kamwethya, KEMRI, Kenya
- Leveraging multiplex bead-based immunoassays to identify undiagnosed enteric fever: a prospective, hospital-based fever study in rural South and Southeast Asia
Sophie Kang, University of Oxford, Mahidol-Oxford Tropical Medicine Research Unit (MORU)
- A Machine Learning Approach to Defining and Predicting the Scale of Typhoid Fever Outbreaks
Zeean Pithawala, Yale University, USA

17:30-19:30

Evening Reception

Wednesday, March 25

07:30-08:30	Sunrise Session Value Case for Combination Vaccines Moderator: Farzana Bano Muhib and Muhibul Kashem TCV Combination Vaccines, and Public Health and Market Opportunity Analysis for Bi-valent Vaccine <i>Farzana Muhib and Muhibul Kashem, PATH</i>
8:30-9:30	Plenary No Silver Bullets: Integrating AMR, WASH, and Climate This plenary focuses on the importance of integrating approaches beyond vaccines, including antimicrobial resistance, water and sanitation, and environmental and climate considerations, to strengthen prevention and control strategies for typhoid and other invasive salmonelloses.
9:30-10:00	Coffee Break Poster Viewing
10:00-11:30	Symposium Informing Equitable and Impactful Typhoid Vaccine Distribution through Environmental and Serological Surveillance Moderators: Nicholas Grassly and Jessica Seidman <ul style="list-style-type: none">• Expanding seroincidence estimation across settings: methodological insights from IgA and IgG antibody kinetics <i>Kristen Aiemjoy, UC Davis, Mahidol University Faculty of Tropical Medicine</i>• Integrating seroepidemiologic data into global enteric fever burden models for TCV decision-making <i>Zean Pithawala, Yale School of Public Health</i>• Assessing enteric fever seroincidence following TCV introduction <i>James Meiring, University of Liverpool</i> <i>Michael Owusu, Kwame Nkrumah University of Science and Technology</i>• Durability of typhoid vaccine impact following an initial campaign in Vellore, India: evidence from environmental surveillance <i>Venkata Mohan Raghava, Christian Medical College, Vellore, India</i>• Early detection of emerging <i>Salmonella Typhi</i> genotypes in Nigeria using environmental surveillance <i>Veronica Ogunleye, University of Ibadan, Nigeria</i>• Scaling typhoid environmental surveillance to the national level in Ghana <i>Michael Owusu, Kwame Nkrumah University of Science & Technology, Ghana</i>

11:30-13:00	<p>Abstract Session Evolution in Action: Genomics and Resistance</p> <ul style="list-style-type: none"> Global phylogeographic analysis of the emergence and spread of Antimicrobial Resistant typhoid <i>Zoe Anne Dyson, LSHTM</i> Emergence and circulation of ceftriaxone-resistant <i>Salmonella Typhi</i> 4.3.1.2.B1 strain in Bangladesh <i>Yogesh Hooda, Child Health Research Foundation</i> Antimicrobial Resistance, Genetic Adaptations and Biofilm Formation in <i>Salmonella Typhi</i> Isolates from Asymptomatic Carriers <i>Peter Muturi, KEMRI</i> An updated population structure and nomenclature of invasive <i>Salmonella</i> Typhimurium <i>Ine Hoeben, University of Antwerp</i> Integrated genomic, epidemiologic, and phenotypic investigation of XDR <i>Salmonella</i> Isangi in Malawi and South Africa <i>Peter Johnston, University of Liverpool</i> AmpliconTyper – tool for analysing ONT multiplex PCR data from environmental and other complex samples <i>Anton Spadar, LSHTM</i>
13:00-14:30	<p>Lunch</p>
13:30-14:30	<p>Workshop Shaping the Future of Enteric Fever Treatment Trials: Populations, Outcomes, and Priorities</p> <p>Moderators: Megan Carey and Chris Parry</p> <ul style="list-style-type: none"> Overview of global antimicrobial resistance and introduction to session format and objectives <i>Megan Carey, LSHTM, Amsterdam Institute for GHD, MMGH Consulting</i> Defining the key questions for the next generation of randomized controlled treatment trials for typhoid fever <i>Christopher Parry, University of Oxford, Liverpool School of Tropical Medicine</i> Identifying regional treatment challenges and trial priorities for typhoid fever in India <i>Priscilla Rupali, Christian Medical College, Vellore</i> Identifying regional treatment challenges and trial priorities for typhoid fever in Kenya <i>TBD</i> Identifying regional treatment challenges and trial priorities for typhoid fever in Pakistan <i>Farah Naz Qamar, Aga Khan University</i> Identifying regional treatment challenges and trial priorities for typhoid fever in Malawi <i>James Meiring, University of Liverpool, Malawi Liverpool Wellcome Programme</i>

14:30-16:00

Symposium

Correlates of Protection for Vaccine Development

Moderators: Malick Gibani, Maheshi Ramasamy, and Xinxue Liu

- Defining the Correlate of Protection for Typhoid Conjugate Vaccine Using Three-Stage Bayesian Modelling
Yiyuan Zhang, Oxford Vaccine Group
- Identifying Immunological Correlates of Protection from a Vaccine Controlled Human Infection Model of *Salmonella Paratyphi A*
Naina McCann, Oxford Vaccine Group
- Establishing a Controlled human infection model of *Salmonella Paratyphi A* in endemic setting
Saba Siddiqui, Aga Khan University
- Using GMMA Vaccines to Identify Mechanisms of Protection against iNTS
Leila Godfrey, University of Oxford
- Establishing Correlates of Immunity from Naturally Exposed Populations
Agness Lakudzala, Malawi-Liverpool Wellcome Research Programme
- Using Human Challenge Models to Define Correlates of Protection against *Salmonella Typhimurium*
Anna Rydlova, Imperial College London

16:00-16:30

Coffee Break

Poster Viewing

16:30-18:00

Abstract Session

From Bench to Breakthrough: Immunology & Vaccine Development

- Safety and immunogenicity results of a phase I clinical trial of bivalent typhoid and paratyphoid A conjugate vaccine in healthy Indian adult participants
Pavankumar Daultani, Zydus Lifesciences Ltd.
- Results from phase 1/2a RCT to evaluate the safety & immunogenicity of a trivalent vaccine against iNTS & typhoid in healthy European and African adults
Yasir Shitu Isa, GSK Vaccines Institute for Global Health
- Phase 2 trial in sub-Saharan Africa to assess the safety and immunogenicity of a Trivalent *Salmonella* Conjugate Vaccine (TSCV)
Wilbur Chen, University of Maryland School of Medicine
- A Phase 2/3 experience to assess the safety and immunogenicity of a bivalent typhoid - paratyphoid A vaccine in India and Kenya
Sanket Gaidhane, Serum Institute of India
- Humoral mechanisms by which asymptomatic malaria exposures in the community may attenuate naturally acquired immunity against iNTS disease in Malawian children
Agness Ethel Lakudzala, Malawi-Liverpool Wellcome Trust

Thursday, March 26

7:30-8:30

Sunrise Session

Vaccine Schedule Modelling

Moderators: Catherine Wegner, Virginia Pitzer, and Megan Carey

- Models for the Transmission Dynamics of Typhoid Fever
Kyra Grantz, Institute for Disease Modeling, Gates Foundation
- Real-World Data to Calibrate Vaccine Effectiveness and Duration of Protection
Alina Muellenmeister, Burnet Institute
- Cost-Effectiveness Analysis: Parameter Identification in Light of Data Gaps
Tigist Menkir, Stanford University
- Comparative Insights: Synthesizing Findings and Identifying Key Sources of Uncertainty
Catherine Wenger, Yale School of Public Health
- Panel discussion: Implications of Models for Informing Vaccine Recommendations
Firdausi Qadri, icddr,b, Farah Qamar, Aga Khan University, and Jacob John, CMC Vellore

8:30-9:30

Plenary

Next-Generation Tools and Innovation: Advancing Diagnostics, Vaccines, and Surveillance

This plenary focuses on emerging tools shaping the future of typhoid and other invasive salmonelloses, with particular attention to advances in diagnostics, vaccines, and epidemiological and environmental surveillance.

9:30-10:00

Coffee Break

Poster Viewing

10:00-12:00

Abstract Session

Evidence that Moves Policy: Getting to Impact

- An Evaluation of Public Knowledge, Attitudes and Prevention Practices Relating to Typhoid Disease in High-Risk Urban and Peri-Urban Areas of Lilongwe, Malawi
Adriano Lubanga, Clinical Research and Education Management Services, Malawi
- Empowering Community Health Volunteers to Strengthen Typhoid Prevention and Immunization Readiness in Nairobi's Informal Settlements
Julia Macharia, Community Health Volunteer CBO, Kenya
- Breaking Barriers: How Local Solutions in Refugee Settlements Triumph Over TCV Vaccine Hesitancy and Shatter Myths:
Muhumuza Umar, Africa CDC
- From vaccine development to policy research and implementation: WHO-led efforts to combat invasive Salmonella disease
Ana Belen Ibarz Pavon, WHO, Switzerland
- Antibiotic treatment for enteric fever in Controlled Human Infection Models (CHIM) at the Oxford Vaccine Group, UK
Margarete Paganotti Vicentine, University of Oxford
- Cost-effectiveness Analysis of Introduction of Typhoid Conjugate Vaccine into Indonesia's National Immunisation Program
Jonathan Hasian Haposan, Universitas Gadjah Mada, Yogyakarta, Indonesia
- Using Anti-Vi IgG and Machine Learning to Infer Typhoid Conjugate Vaccine Coverage after the Malawi National TCV campaign
Priyanka Patel, Malawi Liverpool Wellcome Trust

12:00-13:00	Lunch
13:00-14:30	Abstract Session Late Breakers
14:30-15:00	Coffee Break <i>Poster Viewing</i>
15:00-15:45	Closing Panel Sustaining Momentum and Scaling Impact Against Typhoid and iNTS This session closes the meeting with a forward-looking, interactive conversation on how we collectively sustain momentum and translate progress into lasting impact.
15:45-16:00	Poster Awards
16:00-16:20	Closing Remarks
16:20-16:30	Meeting Adjourned